Methods for forming an expandable tubular body having a plurality of braided filaments including a first filament including platinum or platinum alloy and a second filament including cobalt-chromium alloy. The methods include applying a first phosphorylcholine material directly on the platinum or platinum alloy of the first filament and applying a silane material on the second filament followed by a second phosphorylcholine material on the silane material on the second filament. The first and second phosphorylcholine materials each define a thickness of less than 100 nanometers.

Provided is a stent comprising: a stent skeleton; and a deposition layer containing a plurality of layers deposited on the stent skeleton; each layer of the deposition layer comprising crystalline cilostazol, at least one of the plurality of layers comprising a bioabsorbable polymer, wherein elution of not more than 5% by mass of the crystalline cilostazol occurs by 24 hours after the stent is brought into contact in vitro at 37° C. with an elution medium of a phosphate-buffered sodium chloride solution containing 0.25% by mass of sodium lauryl sulfate.

The present invention relates to novel compositions and methods for reducing or eliminating the thrombogenicity of a graft by modifying the graft with a cell-derived extracellular matrix lacking thrombospondin-2 (TSP2-null ECM) to render it non-thrombogenic when transplanted to a subject in need thereof. The invention also provides a method for improving the biocompatibility of a medical device or an implant by modifying the medical device or implant with a cell-derived TSP2-null ECM, whereby the medical device or implant is rendered non-thrombogenic and pro-migratory.

Disclosed herein is a medical device, comprising a covalently-bonded heparin coating on a substrate, where the covalently bonded heparin coating is the reaction product of (a) an isocyanate-bearing material on or covalently bonded to the substrate and (b) a heparin molecule selected from one of the formulae in the claims. The current invention also relates to a method of forming the medical device, which may be useful as heart stent or intravascular stent that is hemocompatible for preventing the formation of blood clots.

The present invention relates to compositions and methods to provide continuous and controlled release of therapeutic agent(s) during a procedure such as an interventional vascular procedure, e.g., to reduce acute and chronic complications and improve outcomes.

There is provided a method for decreasing leakage of matter from an object to a surrounding, said object being coated with a coating at least partially applied on the object, said coating comprising an at least partially covering layer comprising silver, said object optionally comprising area(s) without said layer, said coating comprising metal particles applied on the layer and optionally on areas without said layer, said metal particles comprising palladium and at least one metal selected from the group consisting of gold, ruthenium, rhodium, osmium, iridium, niobium, neodymium and platinum and wherein the amount of the metal particles is in the interval 0.01-8 μg/cm.sup.2. Advantages include that leakage of matter such as latex allergens of metal ions can be reduced while the coating is both biocompatible and antimicrobial. Further, the blood clotting can be reduced.

An absorbable stent includes an absorbable matrix. The matrix includes a number of wave-shaped rings connected by connection units and arranged in an axial direction. The wave-shaped ring includes a number of waves arranged in a circumferential direction. A peak, a valley and a support connecting the peak and the valley form the wave. Two adjacent wave-shaped rings and the connection unit form a closed side supporting unit. The matrix has a volume of 4 μm to 40 μm per unit blood vessel area. The absorbable stent has sufficient radial supporting strength of no less than 55 kPa for clinical applications. Moreover, the volume of the matrix per unit blood vessel area is less than volumes of existing stents. When the absorbable stent and existing stents are made of the same material, the absorbable stent has a shorter degradation and absorption cycle.

The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.

An absorbable implantable medical device made of iron-based alloy, including a base made of iron-based alloy and a complex, wherein the complex includes a complexing agent. In a physiological solution, the base made of iron-based alloy can react with the complexing agent to generate a water-soluble iron complex having solubility in the physiological solution of no less than 10 mg/L. A corrosion product generated after the absorbable implantable medical device made of iron-based alloy is implanted in a human body can be quickly metabolized/absorbed by the body.

The present invention relates to compounds for medical use in the treatment or in the prevention or in the diagnosis of arterial or venous thromboembolism.